Published in Gynecol Oncol on November 01, 1992
In vitro activity of pertuzumab in combination with trastuzumab in uterine serous papillary adenocarcinoma. Br J Cancer (2009) 1.20
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer (2008) 1.15
HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer (2008) 1.14
Body mass index as a prognostic factor in endometrioid adenocarcinoma of the endometrium. J Natl Med Assoc (2006) 1.08
Her-2/neu testing and therapy in gastroesophageal adenocarcinoma. Patholog Res Int (2010) 1.05
Target-specific, histology-independent, randomized discontinuation study of lapatinib in patients with HER2-amplified solid tumors. Invest New Drugs (2010) 1.00
Cisplatin resistance in gastric cancer cells is associated with HER2 upregulation-induced epithelial-mesenchymal transition. Sci Rep (2016) 0.97
Molecular pathogenesis of endometrial and ovarian cancer. Cancer Biomark (2010) 0.95
Target-specific randomized discontinuation trial design: a novel approach in molecular therapeutics. Invest New Drugs (2009) 0.93
Differential sensitivity to platinum-based chemotherapy in primary uterine serous papillary carcinoma cell lines with high vs low HER-2/neu expression in vitro. Am J Obstet Gynecol (2010) 0.92
Prognostic biomarkers in endometrial and ovarian carcinoma. Virchows Arch (2014) 0.90
Development of targeted therapy in uterine serous carcinoma, a biologically aggressive variant of endometrial cancer. Expert Rev Anticancer Ther (2012) 0.90
Are biopsy specimens predictive of HER2 status in gastric cancer patients? Dig Dis Sci (2012) 0.88
Immunohistochemical determination of HER-2/neu, c-Kit (CD117), and vascular endothelial growth factor (VEGF) overexpression in malignant melanoma. J Cancer Res Clin Oncol (2003) 0.86
Higher sensitivity to patupilone versus paclitaxel chemotherapy in primary uterine serous papillary carcinoma cell lines with high versus low HER-2/neu expression in vitro. Gynecol Oncol (2010) 0.86
Modulation of P-gp expression by lapatinib. Invest New Drugs (2010) 0.81
Characterization of EN-1078D, a poorly differentiated human endometrial carcinoma cell line: a novel tool to study endometrial invasion in vitro. Reprod Biol Endocrinol (2007) 0.81
Low levels of cathepsin D are associated with a poor prognosis in endometrial cancer. Br J Cancer (1999) 0.79
Afatinib demonstrates remarkable activity against HER2-amplified uterine serous endometrial cancer in vitro and in vivo. Br J Cancer (2014) 0.78
Enhancement of erbB2 and erbB3 expression during oral oncogenesis in diabetic rats. J Cancer Res Clin Oncol (2007) 0.78
The validation of a novel method combining both HER2 immunohistochemistry and HER2 dual-colour silver in situ hybridization on one slide for gastric carcinoma testing. J Transl Med (2014) 0.77
Human epidermal growth factor receptor-2 overexpression and amplification in metastatic and recurrent high grade or type 2 endometrial carcinomas. Onco Targets Ther (2013) 0.75
High nuclear expression of proteasome activator complex subunit 1 predicts poor survival in soft tissue leiomyosarcomas. Clin Sarcoma Res (2016) 0.75
erbB2 Overexpression in Uterine Serous Cancer: A Molecular Target for Trastuzumab Therapy. Obstet Gynecol Int (2011) 0.75
A phase I trial of combination trastuzumab, lapatinib, and bevacizumab in patients with advanced cancer. Invest New Drugs (2014) 0.75
Tumor suppressor role of miR-3622b-5p in ERBB2-positive cancer. Oncotarget (2017) 0.75
Hypermethylation of the hMLH1 promoter in colon cancer with microsatellite instability. Cancer Res (1998) 4.39
Microsatellite instability in colorectal cancer: different mutator phenotypes and the principal involvement of hMLH1. Cancer Res (1998) 3.36
Mutations in AXIN2 cause colorectal cancer with defective mismatch repair by activating beta-catenin/TCF signalling. Nat Genet (2000) 3.33
T-DNA insertional mutagenesis for functional genomics in rice. Plant J (2000) 3.25
Altered expression of hMSH2 and hMLH1 in tumors with microsatellite instability and genetic alterations in mismatch repair genes. Cancer Res (1996) 2.89
17q23 amplifications in breast cancer involve the PAT1, RAD51C, PS6K, and SIGma1B genes. Cancer Res (2000) 2.81
Pseudomyxoma peritonei. Long-term patient survival with an aggressive regional approach. Ann Surg (1994) 2.50
Increased HER2 with U.S. Food and Drug Administration-approved antibody. J Clin Oncol (1999) 2.48
Patterns of recurrence after curative resection of carcinoma of the colon and rectum. Surg Gynecol Obstet (1992) 2.15
Human epithelial ovarian cancer allelotype. Cancer Res (1993) 2.08
Prospective assessment of survival, morbidity, and cost associated with lymphadenectomy in low-risk endometrial cancer. Gynecol Oncol (2012) 2.01
Increased risk for cancer in patients with the Peutz-Jeghers syndrome. Ann Intern Med (1998) 1.96
Low-risk corpus cancer: is lymphadenectomy or radiotherapy necessary? Am J Obstet Gynecol (2000) 1.93
Spontaneous diabetes mellitus in transgenic mice expressing human islet amyloid polypeptide. Proc Natl Acad Sci U S A (1996) 1.81
Discrepancies in clinical laboratory testing of eligibility for trastuzumab therapy: apparent immunohistochemical false-positives do not get the message. J Clin Oncol (2001) 1.76
Identification of a low-risk subset of patients with stage IB invasive squamous cancer of the cervix possibly suited to less radical surgical treatment. Gynecol Oncol (1995) 1.75
PTEN induces chemosensitivity in PTEN-mutated prostate cancer cells by suppression of Bcl-2 expression. J Biol Chem (2001) 1.72
High-resolution crystal structures of delta5-3-ketosteroid isomerase with and without a reaction intermediate analogue. Biochemistry (1997) 1.71
Patterns of failure in grossly resected pancreatic ductal adenocarcinoma treated with adjuvant irradiation +/- 5 fluorouracil. Int J Radiat Oncol Biol Phys (1993) 1.71
Sentinel lymph node biopsy with metastasis: can axillary dissection be avoided in some patients with breast cancer? J Clin Oncol (1999) 1.69
p53 expression in neurofibroma and malignant peripheral nerve sheath tumor. An immunohistochemical study of sporadic and NF1-associated tumors. Am J Clin Pathol (1996) 1.67
Transcriptional complementarity in breast cancer: application to detection of circulating tumor cells. Mol Diagn (2001) 1.67
Designs for group sequential phase II clinical trials. Biometrics (1987) 1.57
Adjuvant chemotherapy versus chemotherapy plus pelvic irradiation for high-risk cervical cancer patients after radical hysterectomy and pelvic lymphadenectomy (RH-PLND): a randomized phase III trial. Gynecol Oncol (1996) 1.55
Cytokeratin immunostaining in differentiating primary ovarian carcinoma from metastatic colonic adenocarcinoma. Mod Pathol (1996) 1.51
Immunohistochemical localization of the 1,25(OH)2D3 receptor and calbindin D28k in human and rat pancreas. Am J Physiol (1994) 1.50
Chronic idiopathic thrombocytopenic purpura. Splenic pathologic features and their clinical correlation. Arch Pathol Lab Med (1993) 1.46
Molecular and cytokinetic pretreatment risk assessment in endometrial carcinoma. Gynecol Oncol (2000) 1.43
Survivin expression in breast cancer predicts clinical outcome and is associated with HER2, VEGF, urokinase plasminogen activator and PAI-1. Ann Oncol (2006) 1.37
EGF/ErbB receptor family in ovarian cancer. Cancer Treat Res (2002) 1.31
Potential therapeutic role of para-aortic lymphadenectomy in node-positive endometrial cancer. Gynecol Oncol (2000) 1.30
Prognostic value of bone marrow angiogenesis in multiple myeloma. Clin Cancer Res (2000) 1.28
Molecular markers in male breast carcinoma. Cancer (1998) 1.26
Primary ovarian carcinoid tumors. Gynecol Oncol (1996) 1.26
Aggressive angiomyxoma of the female pelvis and perineum: a case series. Int J Gynecol Cancer (2006) 1.26
Oligodendrogliomas: reproducibility and prognostic value of histologic diagnosis and grading. J Neuropathol Exp Neurol (2001) 1.25
Prostate-specific antigen as a pretherapy prognostic factor in patients treated with radiation therapy for clinically localized prostate cancer. J Clin Oncol (1993) 1.25
Serous borderline tumor of the paratestis: a report of seven cases. Am J Surg Pathol (2001) 1.25
A method for determination of the methylated constituents of transfer ribonucleic acid. Biochemistry (1974) 1.23
HMSH6 alterations in patients with microsatellite instability-low colorectal cancer. Cancer Res (2000) 1.20
The effect of online status on the impact factors of general internal medicine journals. Neth J Med (2006) 1.19
Solitary fibrous tumor: a study of cytologic features of six cases diagnosed by fine-needle aspiration. Diagn Cytopathol (2001) 1.18
Immunohistochemical localization of transforming growth factor-beta 1 in the nonnecrotizing granulomas of pulmonary sarcoidosis. Am J Respir Crit Care Med (1994) 1.18
Evidence of functional RB protein in epithelial ovarian carcinomas despite loss of heterozygosity at the RB locus. Cancer Res (1994) 1.18
Disseminated cervical adenoma malignum and bilateral ovarian sex cord tumors with annular tubules associated with Peutz-Jeghers syndrome. Gynecol Oncol (1994) 1.18
Staging and therapeutic value of lymphadenectomy in endometrial cancer. Gynecol Oncol (1998) 1.16
Preoperative evaluation of serum CA 125 levels in premenopausal and postmenopausal patients with pelvic masses: discrimination of benign from malignant disease. Am J Obstet Gynecol (1988) 1.16
Deciduoid peritoneal mesothelioma. An unusual phenotype affecting young females. Am J Surg Pathol (1994) 1.16
Activity of lapatinib a novel HER2 and EGFR dual kinase inhibitor in human endometrial cancer cells. Br J Cancer (2008) 1.15
HER2 gene amplification and EGFR expression in a large cohort of surgically staged patients with nonendometrioid (type II) endometrial cancer. Br J Cancer (2008) 1.14
Intracardiac leiomyomatosis: echocardiographic features. Chest (1999) 1.13
Hyperestrogenism: a relevant risk factor for the development of cancer from endometriosis. Gynecol Oncol (2000) 1.13
Morphometric analysis of the "mucocellular layer" overlying colorectal cancer and normal mucosa: relevance to exfoliation and stool screening. Hum Pathol (2000) 1.11
Hematogenous dissemination in corpus cancer. Gynecol Oncol (2001) 1.10
Prognostic significance of p53 immunostaining in epithelial ovarian cancer. J Clin Oncol (1994) 1.10
Extension of useful reagent shelf life beyond manufacturers' recommendations. Cell Markers Committee of the College of American Pathologists. Arch Pathol Lab Med (1998) 1.10
The expression of Fas Ligand by macrophages and its upregulation by human immunodeficiency virus infection. J Clin Invest (1998) 1.09
Ontogeny of Phex/PHEX protein expression in mouse embryo and subcellular localization in osteoblasts. J Bone Miner Res (2002) 1.08
Expression of estrogen receptor isoforms alpha and beta messenger RNA in vaginal tissue of premenopausal and postmenopausal women. Am J Obstet Gynecol (2001) 1.08
Colorectal cancer. Dukes' stage, tumor site, preoperative plasma CEA level, and patient prognosis related to tumor DNA ploidy pattern. Arch Surg (1987) 1.08
Routes of lymphatic spread: a study of 112 consecutive patients with endometrial cancer. Gynecol Oncol (2001) 1.08
Comparison of loss of heterozygosity patterns in invasive low-grade and high-grade epithelial ovarian carcinomas. Cancer Res (1993) 1.08
Diabetes mellitus in cystic fibrosis is characterized by islet amyloidosis. J Clin Endocrinol Metab (1996) 1.08
Early evaluation of combined fluorouracil and leucovorin as a radiation enhancer for locally unresectable, residual, or recurrent gastrointestinal carcinoma. The North Central Cancer Treatment Group. J Clin Oncol (1994) 1.08
Crystal structure of a maltogenic amylase provides insights into a catalytic versatility. J Biol Chem (1999) 1.07
Stage I ovarian epithelial carcinoma: survival analysis following definitive treatment. Gynecol Oncol (1991) 1.07
Islet amyloid polypeptide in human insulinomas. Evidence for intracellular amyloidogenesis. Diabetes (1994) 1.07
Carcinoma of the vulva: analysis of treatment failures. Am J Obstet Gynecol (1982) 1.05
DNA ploidy and cell kinetic measurements as predictors of recurrence and survival in stages B2 and C colorectal adenocarcinoma. Cancer (1991) 1.05
Inhibin A is a sensitive and specific marker for testicular sex cord-stromal tumors. Mod Pathol (1998) 1.04
Colonic cancer during pregnancy: case report and review of the literature. Mayo Clin Proc (1992) 1.01
Wide spectrum screening keratin as a marker of metaplastic spindle cell carcinoma of the breast: an immunohistochemical study of 24 patients. Histopathology (2002) 1.01
Expression of an immediate early gene, IEX-1, in human tissues. Histochem Cell Biol (2001) 1.00
Female urethral adenocarcinoma: immunohistochemical evidence of more than 1 tissue of origin. J Urol (1999) 1.00
Serum sErbB1 and epidermal growth factor levels as tumor biomarkers in women with stage III or IV epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev (1999) 0.99
Evaluating the prognostic significance of preoperative thrombocytosis in epithelial ovarian cancer. Gynecol Oncol (2013) 0.99
A multiple prognostic index predictive of disease outcome after irradiation for clinically localized prostate carcinoma. Cancer (1997) 0.99
Clinicopathologic analysis of uterine malignant mixed müllerian tumors. Gynecol Oncol (1989) 0.99
Ontogeny of the 1,25-dihydroxyvitamin D3 receptor in fetal rat bone. J Bone Miner Res (1996) 0.98
Detection of mammaglobin in the sera of patients with breast cancer. Tumour Biol (2002) 0.98
Purification of tryptase from a human mast cell line. J Leukoc Biol (1990) 0.97
CA 125 in gynecologic practice. Am J Obstet Gynecol (1986) 0.97
Monoclonal antibodies against the human sodium iodide symporter: utility for immunocytochemistry of thyroid cancer. J Endocrinol (1999) 0.96
Surgical management and adjuvant therapy for patients with uterine clear cell carcinoma: a multi-institutional review. Gynecol Oncol (2007) 0.96
Identification of prognostic factors and risk groups in patients found to have nodal metastasis at the time of radical hysterectomy for early-stage squamous carcinoma of the cervix. Gynecol Oncol (1989) 0.96
The epidemiology of ovarian cancer: a population-based study in Olmsted County, Minnesota, 1935-1991. Ann Epidemiol (2000) 0.95